Rejected
at 1:42 a.m. Apr, 18, 2026 ]
by
Ahmed7
Author:
arahe
Type of change:
Updated content
Rationale for change
Palivizumab is pulled from US markets in favor of Nirsevimab
Source: Society Guidelines - https://publications.aap.org/aapnews/news/32817/Sobi-discontinues-RSV-injection-Synagis?autologincheck=redirected
Rejection reason
will address, thank you
Current
Suggested
Physeo
Physeo
Physeo
Physeo
Text
What is used for prevention of respiratory syncytial virus (RSV) in preterm infants?
{{c1::Nirsevimab or palivizumab::2}}
Extra
Nirsevimab is a newly approved monoclonal antibody that is now preferred over palivizumab
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid








Sketchy
Ghost "pals visiting"




Sketchy 2



Watch Bronchiolitis



Watch Bronchiolitis
Picmonic
Empty field
Pixorize


OME
Empty field
Additional Resources
Empty field
One by one
Empty field


